Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 240

1.

Rejection of immunogenic tumor clones is limited by clonal fraction.

Gejman RS, Chang AY, Jones HF, DiKun K, Hakimi AA, Schietinger A, Scheinberg DA.

Elife. 2018 Nov 30;7. pii: e41090. doi: 10.7554/eLife.41090.

2.

Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.

Mondello P, Brea EJ, De Stanchina E, Toska E, Chang AY, Fennell M, Seshan V, Garippa R, Scheinberg DA, Baselga J, Wendel HG, Younes A.

JCI Insight. 2018 Nov 15;3(22). pii: 125568. doi: 10.1172/jci.insight.125568. [Epub ahead of print] No abstract available.

3.

The effects of amine-modified single-walled carbon nanotubes on the mouse microbiota.

Mulvey JJ, Littmann ER, Ling L, McDevitt MR, Pamer EG, Scheinberg DA.

Int J Nanomedicine. 2018 Sep 10;13:5275-5286. doi: 10.2147/IJN.S168554. eCollection 2018.

4.

Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.

Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini M, Rosenblat T, Jurcic JG, Brentjens RJ, Arcila ME, Rampal R, Park JH, Douer D, Katz L, Sarlis N, Tallman MS, Scheinberg DA.

Blood Adv. 2018 Feb 13;2(3):224-234. doi: 10.1182/bloodadvances.2017014175.

5.

A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma.

Zauderer MG, Tsao AS, Dao T, Panageas K, Lai WV, Rimner A, Rusch VW, Adusumilli PS, Ginsberg MS, Gomez D, Rice D, Mehran R, Scheinberg DA, Krug LM.

Clin Cancer Res. 2017 Dec 15;23(24):7483-7489. doi: 10.1158/1078-0432.CCR-17-2169. Epub 2017 Sep 28.

PMID:
28972039
6.

A new mouse expressing human Fcγ receptors to better predict therapeutic efficacy of human anti-cancer antibodies.

Casey E, Bournazos S, Mo G, Mondello P, Tan KS, Ravetch JV, Scheinberg DA.

Leukemia. 2018 Feb;32(2):547-549. doi: 10.1038/leu.2017.293. Epub 2017 Sep 19. No abstract available.

7.

A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.

Chang AY, Dao T, Gejman RS, Jarvis CA, Scott A, Dubrovsky L, Mathias MD, Korontsvit T, Zakhaleva V, Curcio M, Hendrickson RC, Liu C, Scheinberg DA.

J Clin Invest. 2017 Sep 1;127(9):3557. doi: 10.1172/JCI96860. Epub 2017 Sep 1. No abstract available.

8.

Carbon nanotubes exhibit fibrillar pharmacology in primates.

Alidori S, Thorek DLJ, Beattie BJ, Ulmert D, Almeida BA, Monette S, Scheinberg DA, McDevitt MR.

PLoS One. 2017 Aug 28;12(8):e0183902. doi: 10.1371/journal.pone.0183902. eCollection 2017.

9.

CD47 blockade enhances therapeutic activity of TCR mimic antibodies to ultra-low density cancer epitopes.

Mathias MD, Sockolosky JT, Chang AY, Tan KS, Liu C, Garcia KC, Scheinberg DA.

Leukemia. 2017 Oct;31(10):2254-2257. doi: 10.1038/leu.2017.223. Epub 2017 Jul 12. No abstract available.

10.

A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.

Chang AY, Dao T, Gejman RS, Jarvis CA, Scott A, Dubrovsky L, Mathias MD, Korontsvit T, Zakhaleva V, Curcio M, Hendrickson RC, Liu C, Scheinberg DA.

J Clin Invest. 2017 Jun 30;127(7):2705-2718. doi: 10.1172/JCI92335. Epub 2017 Jun 19. Erratum in: J Clin Invest. 2017 Sep 1;127(9):3557.

11.

Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.

Mondello P, Brea EJ, De Stanchina E, Toska E, Chang AY, Fennell M, Seshan V, Garippa R, Scheinberg DA, Baselga J, Wendel HG, Younes A.

JCI Insight. 2017 Mar 23;2(6):e90196. doi: 10.1172/jci.insight.90196.

12.

An immunogenic WT1-derived peptide that induces T cell response in the context of HLA-A*02:01 and HLA-A*24:02 molecules.

Dao T, Korontsvit T, Zakhaleva V, Jarvis C, Mondello P, Oh C, Scheinberg DA.

Oncoimmunology. 2016 Dec 7;6(2):e1252895. doi: 10.1080/2162402X.2016.1252895. eCollection 2017.

13.

Immune reconstitution and remission in CML.

Scheinberg DA.

Blood. 2017 Mar 2;129(9):1064-1065. doi: 10.1182/blood-2017-01-761569. No abstract available. Erratum in: Blood. 2018 Nov 29;132(22):2419.

14.

Erratum to: Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.

Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, Chen Y, Danilova L, Voss MH, Coleman JA, Russo P, Reuter VE, Chan TA, Cheng EH, Scheinberg DA, Li MO, Choueiri TK, Hsieh JJ, Sander C, Hakimi AA.

Genome Biol. 2017 Mar 1;18(1):46. doi: 10.1186/s13059-017-1180-8. No abstract available.

15.

Advances in the clinical translation of nanotechnology.

Scheinberg DA, Grimm J, Heller DA, Stater EP, Bradbury M, McDevitt MR.

Curr Opin Biotechnol. 2017 Aug;46:66-73. doi: 10.1016/j.copbio.2017.01.002. Epub 2017 Feb 7. Review.

16.

Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.

Mondello P, Derenzini E, Asgari Z, Philip J, Brea EJ, Seshan V, Hendrickson RC, de Stanchina E, Scheinberg DA, Younes A.

Oncotarget. 2017 Feb 21;8(8):14017-14028. doi: 10.18632/oncotarget.14876.

17.

Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.

Rafiq S, Purdon TJ, Daniyan AF, Koneru M, Dao T, Liu C, Scheinberg DA, Brentjens RJ.

Leukemia. 2017 Aug;31(8):1788-1797. doi: 10.1038/leu.2016.373. Epub 2016 Dec 7.

18.

Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures.

Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D, Ostrovnaya I, Drill E, Luna A, Weinhold N, Lee W, Manley BJ, Khalil DN, Kaffenberger SD, Chen Y, Danilova L, Voss MH, Coleman JA, Russo P, Reuter VE, Chan TA, Cheng EH, Scheinberg DA, Li MO, Choueiri TK, Hsieh JJ, Sander C, Hakimi AA.

Genome Biol. 2016 Nov 17;17(1):231. Erratum in: Genome Biol. 2017 Mar 1;18(1):46.

19.

Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells.

Brea EJ, Oh CY, Manchado E, Budhu S, Gejman RS, Mo G, Mondello P, Han JE, Jarvis CA, Ulmert D, Xiang Q, Chang AY, Garippa RJ, Merghoub T, Wolchok JD, Rosen N, Lowe SW, Scheinberg DA.

Cancer Immunol Res. 2016 Nov;4(11):936-947. Epub 2016 Sep 28.

20.

Remodeling the Vascular Microenvironment of Glioblastoma with α-Particles.

Behling K, Maguire WF, Di Gialleonardo V, Heeb LE, Hassan IF, Veach DR, Keshari KR, Gutin PH, Scheinberg DA, McDevitt MR.

J Nucl Med. 2016 Nov;57(11):1771-1777. Epub 2016 Jun 3.

21.

Mechanisms of leukemia resistance to antibody dependent cellular cytotoxicity.

Dubrovsky L, Brea EJ, Pankov D, Casey E, Dao T, Liu C, Scheinberg DA.

Oncoimmunology. 2016 Aug 3;5(9):e1211221. eCollection 2016.

22.

Deconvoluting hepatic processing of carbon nanotubes.

Alidori S, Bowman RL, Yarilin D, Romin Y, Barlas A, Mulvey JJ, Fujisawa S, Xu K, Ruggiero A, Riabov V, Thorek DL, Ulmert HD, Brea EJ, Behling K, Kzhyshkowska J, Manova-Todorova K, Scheinberg DA, McDevitt MR.

Nat Commun. 2016 Jul 29;7:12343. doi: 10.1038/ncomms12343.

23.

VEGF-ablation therapy reduces drug delivery and therapeutic response in ECM-dense tumors.

Röhrig F, Vorlová S, Hoffmann H, Wartenberg M, Escorcia FE, Keller S, Tenspolde M, Weigand I, Gätzner S, Manova K, Penack O, Scheinberg DA, Rosenwald A, Ergün S, Granot Z, Henke E.

Oncogene. 2017 Jan 5;36(1):1-12. doi: 10.1038/onc.2016.182. Epub 2016 Jun 6.

24.

Acute myeloid leukaemia.

Khwaja A, Bjorkholm M, Gale RE, Levine RL, Jordan CT, Ehninger G, Bloomfield CD, Estey E, Burnett A, Cornelissen JJ, Scheinberg DA, Bouscary D, Linch DC.

Nat Rev Dis Primers. 2016 Mar 10;2:16010. doi: 10.1038/nrdp.2016.10. Review.

PMID:
27159408
25.

Vascular Targeted Radioimmunotherapy for the Treatment of Glioblastoma.

Behling K, Maguire WF, López Puebla JC, Sprinkle SR, Ruggiero A, O'Donoghue J, Gutin PH, Scheinberg DA, McDevitt MR.

J Nucl Med. 2016 Oct;57(10):1576-1582. Epub 2016 Apr 28.

26.

Opportunities and challenges for TCR mimic antibodies in cancer therapy.

Chang AY, Gejman RS, Brea EJ, Oh CY, Mathias MD, Pankov D, Casey E, Dao T, Scheinberg DA.

Expert Opin Biol Ther. 2016 Aug;16(8):979-87. doi: 10.1080/14712598.2016.1176138. Epub 2016 Apr 27. Review.

27.

Targeted fibrillar nanocarbon RNAi treatment of acute kidney injury.

Alidori S, Akhavein N, Thorek DL, Behling K, Romin Y, Queen D, Beattie BJ, Manova-Todorova K, Bergkvist M, Scheinberg DA, McDevitt MR.

Sci Transl Med. 2016 Mar 23;8(331):331ra39. doi: 10.1126/scitranslmed.aac9647.

28.

T cell receptor mimic antibodies for cancer therapy.

Dubrovsky L, Dao T, Gejman RS, Brea EJ, Chang AY, Oh CY, Casey E, Pankov D, Scheinberg DA.

Oncoimmunology. 2015 Jun 1;5(1):e1049803. eCollection 2016. Review.

29.

Structure of a TCR-Mimic Antibody with Target Predicts Pharmacogenetics.

Ataie N, Xiang J, Cheng N, Brea EJ, Lu W, Scheinberg DA, Liu C, Ng HL.

J Mol Biol. 2016 Jan 16;428(1):194-205. doi: 10.1016/j.jmb.2015.12.002. Epub 2015 Dec 11.

30.

Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1.

Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, de Morais Guerreiro MD, Veomett N, Dubrovsky L, Curcio M, Doubrovina E, Ponomarev V, Liu C, O'Reilly RJ, Scheinberg DA.

Nat Biotechnol. 2015 Oct;33(10):1079-86. doi: 10.1038/nbt.3349. Epub 2015 Sep 21.

31.

Encapsulation of α-Particle-Emitting 225Ac3+ Ions Within Carbon Nanotubes.

Matson ML, Villa CH, Ananta JS, Law JJ, Scheinberg DA, Wilson LJ.

J Nucl Med. 2015 Jun;56(6):897-900. doi: 10.2967/jnumed.115.158311. Epub 2015 Apr 30.

32.

Fibrillous carbon nanotube: an unexpected journey.

McDevitt MR, Scheinberg DA.

Crit Rev Oncog. 2014;19(3-4):261-8. Review.

33.

Synthesis, pharmacokinetics, and biological use of lysine-modified single-walled carbon nanotubes.

Mulvey JJ, Feinberg EN, Alidori S, McDevitt MR, Heller DA, Scheinberg DA.

Int J Nanomedicine. 2014 Sep 4;9:4245-55. doi: 10.2147/IJN.S66050. eCollection 2014. Erratum in: Int J Nanomedicine. 2015;10:595.

34.

Nontranscriptional role of Hif-1α in activation of γ-secretase and notch signaling in breast cancer.

Villa JC, Chiu D, Brandes AH, Escorcia FE, Villa CH, Maguire WF, Hu CJ, de Stanchina E, Simon MC, Sisodia SS, Scheinberg DA, Li YM.

Cell Rep. 2014 Aug 21;8(4):1077-92. doi: 10.1016/j.celrep.2014.07.028. Epub 2014 Aug 14.

35.

Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for α-particle radioimmunotherapy of cancer.

Maguire WF, McDevitt MR, Smith-Jones PM, Scheinberg DA.

J Nucl Med. 2014 Sep;55(9):1492-8. doi: 10.2967/jnumed.114.138347. Epub 2014 Jun 30.

36.

Therapeutic efficacy of an Fc-enhanced TCR-like antibody to the intracellular WT1 oncoprotein.

Veomett N, Dao T, Liu H, Xiang J, Pankov D, Dubrovsky L, Whitten JA, Park SM, Korontsvit T, Zakhaleva V, Casey E, Curcio M, Kharas MG, O'Reilly RJ, Liu C, Scheinberg DA.

Clin Cancer Res. 2014 Aug 1;20(15):4036-46. doi: 10.1158/1078-0432.CCR-13-2756. Epub 2014 May 21.

37.

A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias.

Dubrovsky L, Pankov D, Brea EJ, Dao T, Scott A, Yan S, O'Reilly RJ, Liu C, Scheinberg DA.

Blood. 2014 May 22;123(21):3296-304. doi: 10.1182/blood-2014-01-549022. Epub 2014 Apr 10.

38.

Inhibition of human mitochondrial peptide deformylase causes apoptosis in c-myc-overexpressing hematopoietic cancers.

Sheth A, Escobar-Alvarez S, Gardner J, Ran L, Heaney ML, Scheinberg DA.

Cell Death Dis. 2014 Mar 27;5:e1152. doi: 10.1038/cddis.2014.112.

39.

Self-assembly of carbon nanotubes and antibodies on tumours for targeted amplified delivery.

Mulvey JJ, Villa CH, McDevitt MR, Escorcia FE, Casey E, Scheinberg DA.

Nat Nanotechnol. 2013 Oct;8(10):763-71. doi: 10.1038/nnano.2013.190. Epub 2013 Sep 29.

40.

Approaching untargetable tumor-associated antigens with antibodies.

Dao T, Liu C, Scheinberg DA.

Oncoimmunology. 2013 Jul 1;2(7):e24678. Epub 2013 Apr 30.

41.

Therapeutic antibodies to intracellular targets in cancer therapy.

Veomett N, Dao T, Scheinberg DA.

Expert Opin Biol Ther. 2013 Nov;13(11):1485-8. doi: 10.1517/14712598.2013.833602. Epub 2013 Aug 31.

PMID:
23991764
42.

Carbon nanotubes as vaccine scaffolds.

Scheinberg DA, McDevitt MR, Dao T, Mulvey JJ, Feinberg E, Alidori S.

Adv Drug Deliv Rev. 2013 Dec;65(15):2016-22. doi: 10.1016/j.addr.2013.07.013. Epub 2013 Jul 27. Review.

43.

A self-assembling short oligonucleotide duplex suitable for pretargeting.

Mallikaratchy P, Gardner J, Nordstrøm LU, Veomett NJ, McDevitt MR, Heaney ML, Scheinberg DA.

Nucleic Acid Ther. 2013 Aug;23(4):289-99. doi: 10.1089/nat.2013.0425. Epub 2013 Jul 13.

44.

Reaching un-drugable intracellular targets with the long arm of antibodies.

Scheinberg DA, Dao T, Liu C.

Oncotarget. 2013 May;4(5):647-8. No abstract available.

45.

Deploying RNA and DNA with Functionalized Carbon Nanotubes.

Alidori S, Asqiriba K, Londero P, Bergkvist M, Leona M, Scheinberg DA, McDevitt MR.

J Phys Chem C Nanomater Interfaces. 2013 Mar 21;117(11):5982-5992.

46.

Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

Dao T, Yan S, Veomett N, Pankov D, Zhou L, Korontsvit T, Scott A, Whitten J, Maslak P, Casey E, Tan T, Liu H, Zakhaleva V, Curcio M, Doubrovina E, O'Reilly RJ, Liu C, Scheinberg DA.

Sci Transl Med. 2013 Mar 13;5(176):176ra33. doi: 10.1126/scitranslmed.3005661.

47.

Dysregulation of IRP1-mediated iron metabolism causes gamma ray-specific radioresistance in leukemia cells.

Haro KJ, Sheth A, Scheinberg DA.

PLoS One. 2012;7(11):e48841. doi: 10.1371/journal.pone.0048841. Epub 2012 Nov 14.

48.

Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells.

Haro KJ, Scott AC, Scheinberg DA.

Blood. 2012 Sep 6;120(10):2087-97. doi: 10.1182/blood-2012-01-404509. Epub 2012 Jul 24.

49.

Familial Alzheimer disease presenilin-1 mutations alter the active site conformation of γ-secretase.

Chau DM, Crump CJ, Villa JC, Scheinberg DA, Li YM.

J Biol Chem. 2012 May 18;287(21):17288-96. doi: 10.1074/jbc.M111.300483. Epub 2012 Mar 29.

50.

Actinium-225 in targeted alpha-particle therapeutic applications.

Scheinberg DA, McDevitt MR.

Curr Radiopharm. 2011 Oct;4(4):306-20. Review.

Supplemental Content

Loading ...
Support Center